NCT04699721View on ClinicalTrials.gov

Clinical Study of Neoadjuvant Chemotherapy and Immunotherapy Combined With Probiotics in Patients With Resectable NSCLC

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

July 1, 2020

Primary Completion Date

September 30, 2027

Study Completion Date

December 31, 2027

Conditions
Non-small Cell Lung Cancer Stage IINon-small Cell Lung Cancer Stage ⅢANon-small Cell Lung Cancer Stage IIIB
Interventions
DRUG

nivolumab 4.5mg/kg+Paclitaxel (albumin-bound type) 260mg / m2+ Carboplatin AUC5

3 cycles of nivolumab+Paclitaxel (albumin-bound type)+ Carboplatin AUC5 (21 days/cycle); as well as BiFico (oral taking, 4 capsules/time, 2 times per day)

Trial Locations (1)

410008

Xiangya Hospital of Central South University, Changsha

All Listed Sponsors
lead

Xiangya Hospital of Central South University

OTHER